Safinamide, for advanced Parkinson’s disease ……


Safinamide, (an alpha-aminoamide derivative, see the structure)  is believed to have a novel dual mechanism of action based on the enhancement of the dopaminergic function and reduction of glutamatergic activity by inhibiting glutamate release. Encouraged by this fact safinamide,  has been developed by Merck Serono.  First Phase III trial results are  really encouraging. Hope this research will go a long way to help an  estimated  3 million people in the industrialized countries, who  suffer from Parkinson’s disease.

The results indicate that safinamide, when used adjunctively to existing dopaminergic therapies for study patients in mid-to-late stages of Parkinson’s disease, increases daily “ON” time of motor functioning,” said Dr. Bernhard Kirschbaum, (Merck Serono’s Executive VP for Global Research and Development).  I am sure  these  results will be,    a further step towards  providing the  patients and doctors with urgently needed new treatment possibilities in the Neurodegenerative Diseases therapeutic area. More..


Leave a Reply

Fill in your details below or click an icon to log in: Logo

You are commenting using your account. Log Out /  Change )

Google+ photo

You are commenting using your Google+ account. Log Out /  Change )

Twitter picture

You are commenting using your Twitter account. Log Out /  Change )

Facebook photo

You are commenting using your Facebook account. Log Out /  Change )


Connecting to %s